Iomab-B Shows Promise as Transplant Conditioning Regimen

Iomab-B Shows Promise as Transplant Conditioning Regimen

283256

Iomab-B Shows Promise as Transplant Conditioning Regimen

Iomab-B shows promise as a conditioning regimen for bone marrow transplant in patients older than 55 with active relapsed or refractory acute myeloid leukemia (AML), according to early data from the ongoing SIERRA trial, which an independent committee has determined can continue to full enrollment. Recently presented data from the trial support the efficacy and safety of this investigational treatment by Actinium Pharmaceuticals. An independent data monitoring committee (DMC) is responsible for ensuring that a…

You must be logged in to read/download the full post.